Captrust Financial Advisors Coherus Bio Sciences, Inc. Transaction History
Captrust Financial Advisors
- $33 Billion
- Q3 2024
A detailed history of Captrust Financial Advisors transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 18,789 shares of CHRS stock, worth $28,559. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,789
Previous 11,396
64.87%
Holding current value
$28,559
Previous $19,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CHRS
# of Institutions
135Shares Held
77.9MCall Options Held
40.7KPut Options Held
50.1K-
Black Rock Inc. New York, NY11.8MShares$17.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$17.2 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$15.8 Million0.3% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$4.61 Million0.18% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.86MShares$4.34 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $118M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...